Related Experiment Video
Updated: Jul 2, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic blockage: a new treatment for glioblastoma
Background:
Angiogenesis is common in cancer and reflects the requirement for a vascular network to support continued uncontrolled growth. Two strategies of antiangiogenic therapy have emerged; one targeting VEGF (growth-factor-ligand-based antagonists) and the second targeting VEGF receptor (receptor-based antagonists, small-molecule tyrosine kinase inhibitors).
Methods:
The literature as reviewed by Reardon et al. [1] regarding treatment of recurrent high-grade gliomas (HGG) with antiangiogenic therapy (predominantly ligand-based and administered in conjunction with cytotoxic chemotherapy) reports response rates of 30 - 60% and 6-month progression-free survival of 25 - 50%. Problems include new antiangiogenic-class side effects and control of administration and timing in relation to surgery.
Results/Conclusions:
Ligand-based antiangiogenic therapy is a compelling targeted therapy for HGG and will continue to emerge as an important antiglioma therapy. Further studies are required to define the population of patients in whom this therapy is of benefit, identify the optimal dose and schedule, characterize the value of co-administered (cytotoxic and targeted) therapies and establish validated response measures.
Insights
Ligand-based antiangiogenic therapy shows promise for high-grade gliomas (HGG), offering significant response rates. Further research is needed to optimize its use and patient selection for this targeted cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and a target for cancer therapies.
- Antiangiogenic therapies primarily target Vascular Endothelial Growth Factor (VEGF) through ligand-based or receptor-based antagonists.
- High-grade gliomas (HGG) exhibit common angiogenesis, necessitating effective therapeutic strategies.
Discussion:
- Review of literature on antiangiogenic therapy for recurrent HGG indicates response rates of 30-60% and 6-month progression-free survival of 25-50% when used with chemotherapy.
- Challenges in antiangiogenic therapy include managing class-specific side effects and coordinating treatment timing with surgery.
- Ligand-based antiangiogenic agents are a compelling targeted therapy for HGG.
Key Insights:
- Ligand-based antiangiogenic therapy demonstrates notable efficacy in treating high-grade gliomas.
- Current treatment paradigms face challenges related to side effects and treatment administration.
- The combination of antiangiogenic therapy with cytotoxic chemotherapy yields significant response rates.
Outlook:
- Further clinical studies are essential to identify optimal patient populations, dosing, and scheduling for antiangiogenic therapy in HGG.
- Investigating the synergistic effects of combined cytotoxic and targeted therapies is crucial.
- Developing validated response measures is necessary to accurately assess treatment outcomes.
